Product Details
| Product Name:
SSR 69071 |
CAS No.:
344930-95-6 |
| Supply Ability:
10g |
Release date:
2026/04/20 |
Product Introduction
Bioactivity
| Name | SSR 69071 |
| Description | SSR69071 is a potent, orally active, and selective inhibitor of neutrophil elastase, displaying higher affinity for human elastase (Ki = 0.0168 nM) compared to rat (Ki = 3 nM), mouse (Ki = 1.8 nM), and rabbit (Ki = 58 nM) elastases [2]. It reduces myocardial infarct size following ischemia-reperfusion injury [1] and has potential for treating chronic obstructive pulmonary diseases, asthma, emphysema, cystic fibrosis, and various inflammatory diseases. |
| In vitro | SSR69071 is a potent inhibitor of human leukocyte elastase (HLE), with an inhibition constant (K i ) of 0.0168±0.0014 nM and an inactivation process constant (k on ) of 0.183±0.013 10 6 /mol sr [2]. It is also a competitive and slow tight-binding inhibitor in vitro, with a K i value of 16.8 pM [3]. |
| In vivo | SSR69071, when administered intravenously at a dose of 3 mg/kg, significantly diminishes cardiac infarct size if given before ischemia or immediately before reperfusion (?37%, P<0.05), and notably reduces cardiac elastase activity upon administration just prior to reperfusion [1]. In oral treatment scenarios, SSR69071 demonstrates dose-dependent effectiveness in inhibiting human leukocyte elastase (HLE) in bronchoalveolar lavage fluid from mice (ED50=10.5 mg/kg p.o.) and markedly reduces acute lung hemorrhage induced by HLE in mice (ED50=2.8 mg/kg p.o.) [2]. Additionally, SSR69071 effectively prevents carrageenan- and HLE-induced paw edema in rats at specific effective doses (ED30=2.2 mg/kg and ED30=2.7 mg/kg, respectively) following oral administration [2]. This research utilized male New Zealand white rabbits weighing 2-3 kg as the animal model [1], with SSR69071 dissolved in methane sulphonic acid before dilution in 0.9% saline for intravenous (i.v.) administration. The pivotal findings demonstrate that treatment with SSR69071 just prior to reperfusion significantly curtails cardiac elastase activity. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Shipping with blue ice/Shipping at ambient temperature. |
| Keywords | SSR-69071 | SSR69071 | SSR 69071 |
| Inhibitors Related | PMSF | AEBSF hydrochloride | Imidazole | Subtilisin | p-Aminobenzamidine dihydrochloride | Chymotrypsin | Proteinase K | Aprotinin | Ac-Ala-OH | Trypsin | FOY 251 | Benzamidine hydrochloride |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
Recommended supplier
| Product name |
Price |
|
Suppliers |
Update time |
|
|
|
|
Moxin Chemicals
|
2025-12-16 |
United States